Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Open access
Fernández, Ariel, Sanguino, Angela, Peng, Zhenghong, Ozturk, Eylem, Chen, Jianping, Crespo, Alejandro, Wulf, Sarah, Shavrin, Aleksander, Qin, Chaoping, Ma, Jianpeng, Trent, Jonathan, Lin, Yvonne, Han, Hee-Dong, Mangala, Lingegowda S., Bankson, James A., Gelovani, Juri, Samarel, Allen, Bornmann, William, Sood, Anil K., Lopez-Berestein, Gabriel·2007·Journal of Clinical Investigation

Abstract

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci32373

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 158

Metadata

Authors
Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H.-D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G.
Venue
Journal of Clinical Investigation
Published
2007-12-03
Volume
117
Issue
12
Pages
4044-4054
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2102050170
Cited by
158
References
2
FWCI
17.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. https://app.cochat.ai/papers/10.1172/jci32373
The paper
Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H.-D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation. https://doi.org/10.1172/jci32373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.